Dr. Toyos is recruiting more participants for a larger trial on hair loss treatments. The discussion mentions Minoxidil, finasteride, and RU58841 as potential treatments.
A 22-year-old with high estradiol levels is considering starting finasteride for hair loss. They have an upcoming endocrinologist appointment to discuss whether they should proceed with the treatment.
The conversation discusses experiences with topical dutasteride for hair loss, comparing formulations from FUEClinic, MinoxidilMax, and Strut. Users share their results and side effects, with some preferring topical over oral treatments to minimize systemic absorption.
A human trial involving verteporfin for hair regeneration, with the results showing some regrowth of 1-2 hairs in an area where a follicular unit was extracted. The conversation also suggested that future studies should involve higher doses and more frequent injections.
Astaxanthin may cause increased hair shedding, affecting even transplanted hair and eyebrows. The user has tried various treatments for androgenic alopecia, including minoxidil, finasteride, and RU58841.
The conversation discusses the use of Verteporfin in hair loss treatment. It suggests that Verteporfin could potentially regenerate hair follicles instead of forming scars, providing an unlimited donor supply for hair transplants.
The user experienced noticeable hair regrowth after using minoxidil and stemoxydine together, despite initial shedding. They believe stemoxydine helps hair grow back faster, working well with minoxidil.
Clinical studies by Dr. Barghouthi and Dr. Bloxham indicate that Verteporfin, when used with FUE and FUT hair transplantation methods, shows promise in hair follicle regeneration and minimal scarring due to its ability to inhibit Yes-associated protein (YAP). Microneedling at depths of 3-3.5mm, combined with Verteporfin, could potentially reactivate dormant follicles, although the optimal dosage and application method are still under investigation. Concerns remain about the DHT sensitivity of regenerated follicles, highlighting the need for further research to optimize trauma levels and Verteporfin concentrations to achieve effective and scar-free hair regeneration.
Verteporfin is being explored for hair regeneration, with unofficial trials and updates shared online. Efforts are being made to encourage more surgeons to trial verteporfin for donor hair regeneration.
A 24-year-old is experiencing aggressive hair shedding despite past success with mesotherapy and minoxidil, and is considering adding treatments like Expecia, dermapen, or a hair transplant. Many suggest using finasteride to maintain hair, as it is necessary even after a transplant, and side effects are rare and reversible.
The user is experiencing scalp irritation from using RU58841 with a 70% ethanol and 30% propylene glycol vehicle and is considering switching to a less irritating vehicle, such as 30% ethanol with 70% squalane or emu oil. They are seeking feedback on the effectiveness and irritation levels of these alternative carriers.
A user is experiencing increased hair shedding after using a homemade topical finasteride mixture with stemoxydine for six weeks. They are concerned about whether the low dose could cause shedding so early.
Dermal incision with verteporfin is being explored as a potential hair loss treatment by dermatologist Melissa Toyos, with promising before-and-after photos shared on social media. The conversation discusses its potential effectiveness compared to other treatments like Minoxidil, Finasteride, and RU58841.
The conversation discusses DIY cosmetic procedures like PRP, mesotherapy, and micro-needling, with some users experimenting with Minoxidil, finasteride, and RU58841 for hair loss. It highlights a community of mostly older women performing these treatments themselves.
Using Stemoxydine, a hair growth promoter, in conjunction with Fin and Minoxidil to help counter shedding induced by the latter two treatments. Another user also shared their experience of using Stemoxydine for three months along with dermastamp.
The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.
The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references upcoming trial data from Shiseido in Japan.
Creating a topical solution combining finasteride and stemoxydine to treat hair loss, and the discussion of whether 15mg of finasteride would be sufficient for 60ml solvent.
The conversation discusses the potential of using topical estrogen treatments for hair loss without systemic absorption, highlighting challenges and possible solutions like using estriol. It also mentions other treatments like topical finasteride, microneedling, and scalp massage, while noting the limitations and side effects of current options.
The conversation discusses the benefits of combining scalp stem cell treatments and exohealer with RF microneedling before a hair transplant. The original poster recommends these treatments for better results.
A 22-year-old male experienced hair loss potentially linked to escitalopram, which stopped after switching to vortioxetine. His depressive symptoms improved with continued treatment.
Finasteride has no effect on the user's estradiol levels, and body fat may influence aromatization. The user is on testosterone replacement therapy and uses everyday injections to manage high RBC count, with plans to measure DHT, DHEA-S, and pregnenolone levels.
The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.
Research and science related to a minor improvement in hair growth caused by the use of verteporfin, as well as potential treatments such as Minoxidil, Finasteride, and RU58841.
Verteporfin is discussed as a potential treatment for hair regrowth, but skepticism exists about its effectiveness in regenerating extracted hair follicles. The conversation also mentions the possibility of needing a hair transplant by 2028.
Volunteers using finasteride and minoxidil are needed to test if intense calf raises increase hair shedding. The goal is to see if overexertion of leg muscles affects hair loss.
SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
A 30-year-old is seeking advice on hair loss treatment, currently using oral minoxidil, finasteride, mesotherapy, and a supplement. They are experiencing shedding and are anxious about the effectiveness of the treatment, asking if they should continue or consider other options like topicals or microneedling.
The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.